# University of Pittsburgh MACS/WIHS CCS

> **NIH NIH U01** · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · 2020 · $4,055,102

## Abstract

PROJECT SUMMARY/ABSTRACT
The overarching strategy of the University of Pittsburgh (Pitt) clinical research site (CRS) together with our
collaborative clinical site at The Ohio State University (OSU) of the Multicenter AIDS Cohort Study
(MACS)/Woman’s Interagency HIV Study (WIHS) Combined Cohort Study (MACS/WIHS CCS) is to support,
complement and accelerate the CCS unified scientific agenda (USA) by leveraging the strengths and scientific
expertise of CRS investigators. We propose to continue to expand on our 35 years of extensive research on the
natural history of HIV infection. The central hypothesis of this grant application is that, as men and women with
chronic HIV infection age, they increase their risks for serious, life-shortening comorbidities beyond those of
comparable age, uninfected persons, and this could differ between men and women. As directed by NIH RFA-
HL-19-008, the CRS will provide robust and inclusive leadership focused on five specific aims of the USA, and
targeted collaborative support for the five other aims, to improve our understanding of the epidemiologic, clinical,
virologic, immunologic, and behavioral relationships of HIV infection to chronic comorbidities in men and women
that represent the current HIV epidemic in the United States. The CRS will also contribute longitudinal data and
biological specimens for collaborative research projects on HIV led by CCS and non-CCS investigators. This
research is important to fulfill our mission of improving clinical management, increasing survival and controlling,
preventing and curing HIV infection. The CRS will provide the most current and innovative epidemiological,
clinical and laboratory methods and psychosocial research protocols to accomplish our 5 leadership specific
aims. The Pitt/OSU CRS will be led by a triumvirate of MPIs and several CoIs with broad expertise needed to
lead five highly specialized CCS USA Specific Aims (Aim 2: Pulmonary/Sleep [Morris]; Aim 3: Neurocognitive
[Becker]; Aim 6: HIV/Pathogenesis [Macatangay]; Aim 7: Psychosocial [Stall]; Aim 9: Platform [Rinaldo,
Kingsley]) and to provide insight for the 5 other Specific Aims (Aim 1: Cardiovascular [Kingsley, Martinson], Aim
4: Aging [Koletar], Aim 5: Cancer [Jenkins], Aim 8: Health Disparities [Krier], Aim 10: Career Development [Sluis-
Cremer]. With this plan the Pitt/OSU CRS addresses the basic justification of the FOA, i.e., that the impact of
HIV, its treatment, and the legacy of immune suppression need to be more fully understood to optimize the health
of people living with HIV.

## Key facts

- **NIH application ID:** 9904786
- **Project number:** 5U01HL146208-02
- **Recipient organization:** UNIVERSITY OF PITTSBURGH AT PITTSBURGH
- **Principal Investigator:** Jeremy James Martinson
- **Activity code:** U01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $4,055,102
- **Award type:** 5
- **Project period:** 2019-04-01 → 2026-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9904786

## Citation

> US National Institutes of Health, RePORTER application 9904786, University of Pittsburgh MACS/WIHS CCS (5U01HL146208-02). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/9904786. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*